United Kingdom in Vitro Diagnostics Investment Opportunities

Analysis and Forecasts to 2015

Product Code GMD09569
Publication Date April 2009
Publisher Global Markets Direct
Product Type Report
Pages 159
ISBN Number not applicable
Change currency
PDF £1,580.00 €1,903 $2,498 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

United Kingdom in Vitro Diagnostics Investment Opportunities

Analysis and Forecasts to 2015

This report is an essential source for in-depth information and data relating to the UK In vitro diagnostic dvices market. It also offers detailed and comprehensive coverage of market revenue, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the in vitro diagnostics market in UK

Scope

  • The report provides in vitro diagnostics information broken down into detailed categories and segments in UK.
  • Total revenues, end users
  • Market shares of all the key competitors.
  • Key pipeline products that are set to shape the market, broken down by sector.
  • Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis.
  • Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
  • Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
  • Key mergers and acquisitions, partnerships, private equity investments and IPOs.
  • Customer, hospitals and physicians data.

Reasons to buy

  • Gain a strong understanding of the in vitro diagnostics devices market in United Kingdom.
  • Evaluate and compare the attractiveness of the market in the country.
  • Identify growth segments and opportunities in each industry sector within the country.
  • Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
  • Analyze the competitiveness of the market in the country and identify hotspots.
  • Develop strategies based on the latest product, brand, expansion and research and development news in the country.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
  • Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Contents

  • 1 List of Tables
  • 1.2 List of Figures
  • 2 Introduction
    • 2.1 What Is This Report About?
  • 3 Definitions of Markets Covered in This Report
    • 3.1 In Vitro Diagnostics
    • 3.2 Clinical Chemistry Test Reagents
      • 3.2.1 Laboratory Reagents
      • 3.2.2 Clinical Chemistry Calibrators and Controls
      • 3.2.3 Clinical Chemistry Rapid Tests
    • 3.3 Immunochemistry Test Reagents
      • 3.3.1 Disease Specific Markers
        • 3.3.1.1 Tumor Markers
        • 3.3.1.2 Cardiac Markers
      • 3.3.2 Disease Specific Test Reagents
        • 3.3.2.1 Auto-Immune Disease
        • 3.3.2.2 Rheumatoid Disease
        • 3.3.2.3 Anemia/ Vitamins
        • 3.3.2.4 Allergy
      • 3.3.3 Drug Related Testing Reagents
        • 3.3.3.1 Therapeutic Drugs
        • 3.3.3.2 Drug of Abuse and Toxicology
      • 3.3.4 Hormone Related Testing Reagents
        • 3.3.4.1 Specific Proteins
        • 3.3.4.2 Fertility and Pregnancy
        • 3.3.4.3 Individual/Specified hormones
        • 3.3.4.4 Specific Organ Function
      • 3.3.5 Immunochemistry Calibrators and Controls
      • 3.3.6 Immunochemistry Rapid Tests
    • 3.4 Blood Test Reagents
      • 3.4.1 Hematology Test Reagents
        • 3.4.1.1 Hematology
        • 3.4.1.2 Immunohaematology
        • 3.4.1.3 Hematology Calibrators and Controls
        • 3.4.1.4 Immunohaematology Controls
      • 3.4.2 Hemostasis Test Reagents
        • 3.4.2.1 Hemostasis
        • 3.4.2.2 Hemostasis Calibrators and Controls
        • 3.4.2.3 Hemostasis Rapid Tests
      • 3.4.3 Tissue Typing Reagents
      • 3.4.4 Monoclonal Antibodies
      • 3.4.5 Cytokines and Immunomodulators
      • 3.4.6 Histology and Cytology Reagents
    • 3.5 Microbiology Test Reagents
      • 3.5.1 Bacteriology Test Reagents
        • 3.5.1.1 Bacteriology Culture
        • 3.5.1.2 Blood Culture
        • 3.5.1.3 Bacteriology Identification and Susceptibility
      • 3.5.2 Microbiology Calibrators and Controls
      • 3.5.3 Microbiology Rapid Tests
    • 3.6 Infectious Immunology Test Reagents
      • 3.6.1 Bacteriology
      • 3.6.2 Virology
        • 3.6.2.1 Hepatitis Viruses
        • 3.6.2.2 Retroviruses
      • 3.6.3 Parasitology
      • 3.6.4 Infectious Immunology Calibrators and Controls
      • 3.6.5 Infectious Immunology Rapid Tests
    • 3.7 Genetic Test Reagents
    • 3.8 Self Testing
    • 3.9 Instruments
  • 4 Healthcare Sector Review
    • 4.1 Healthcare Expenditure
    • 4.2 Healthcare Infrastructure
    • 4.3 Healthcare Policy
    • 4.4 United Kingdom Healthcare Trade Statistics
  • 5 Regulation System
    • 5.1 Medical Equipment Approval Process
      • 5.1.1 Classification of Medical Devices
      • 5.1.2 Conformity Assessment Process
        • 5.1.2.1 Class I devices
        • 5.1.2.2 Class IIa devices
        • 5.1.2.3 Class IIb devices
        • 5.1.2.4 Class III devices
    • 5.2 Medical Device approval fee
    • 5.3 Post Market Surveillance (PMS)
  • 6 Pricing and Reimbursement
    • 6.1 Market Pricing
    • 6.2 Government Policies for Reimbursement
  • 7 Distribution Structure
  • 8 In Vitro Diagnostics In United Kingdom
    • 8.1 In Vitro Diagnostics Cross Country Comparison, Revenue ($ mn), 2000-2015
    • 8.2 In Vitro Diagnostics, United Kingdom, Overall Revenue ($ mn), 2000-2015
    • 8.3 In Vitro Diagnostics, United Kingdom, Company Share (2006-2007)
  • 9 Blood Test Reagents In United Kingdom
    • 9.1 Blood Test Reagents Overall Revenue (2000-2015)
      • 9.1.1 Haematology Test Reagents Revenue (2000-2015)
      • 9.1.2 Hemostasis Test Reagents Revenue (2000-2015)
    • 9.2 Blood Test Reagents Distribution Share (2007-2008)
    • 9.3 Blood Test Reagents, United Kingdom, Company Share (2006-2007)
  • 10 Clinical Chemistry Test Reagents In United Kingdom
    • 10.1 Clinical Chemistry Test Reagents Overall Revenue (2000-2015)
    • 10.2 Clinical Chemistry Test Reagents Distribution Share (2007-2008)
    • 10.3 Clinical Chemistry Test Reagents, United Kingdom, Company Share (2006-2007)
  • 11 Genetic Test Reagents In United Kingdom
    • 11.1 Genetic Test Reagents Overall Revenue (2000-2015)
    • 11.2 Genetic Test Reagents Distribution Share (2007-2008)
    • 11.3 Genetic Test Reagents, United Kingdom, Company Share (2006-2007)
  • 12 Immunochemistry Test Reagents In United Kingdom
    • 12.1 Immunochemistry Test Reagents Overall Revenue (2000-2015)
      • 12.1.1 Disease Specific Markers Revenue (2000-2015)
      • 12.1.2 Disease Specific Test Reagents Revenue (2000-2015)
      • 12.1.3 Drug Related Testing Reagents Revenue (2000-2015)
      • 12.1.4 Hormone Related Testing Reagents Revenue (2000-2015)
    • 12.2 Immunochemistry Test Reagents Distribution Share (2007-2008)
    • 12.3 Immunochemistry Test Reagents, United Kingdom, Company Share (2006-2007)
  • 13 Infectious Immunology Test Reagents In United Kingdom
    • 13.1 Infectious Immunology Test Reagents Overall Revenue (2000-2015)
      • 13.1.1 Virology Revenue (2000-2015)
    • 13.2 Infectious Immunology Test Reagents Distribution Share (2007-2008)
    • 13.3 Infectious Immunology Test Reagents, United Kingdom, Company Share (2006-2007)
  • 14 Instruments In United Kingdom
    • 14.1 Instruments Overall Revenue (2000-2015)
    • 14.2 Instruments Distribution Share (2007-2008)
  • 15 Microbiology Test Reagents In United Kingdom
    • 15.1 Microbiology Test Reagents Overall Revenue (2000-2015)
      • 15.1.1 Bacteriology Test Reagents Revenue (2000-2015)
    • 15.2 Microbiology Test Reagents Distribution Share (2007-2008)
    • 15.3 Microbiology Test Reagents, United Kingdom, Company Share (2006-2007)
  • 16 Self Testing In United Kingdom
    • 16.1 Self Testing Overall Revenue (2000-2015)
    • 16.2 Self Testing Distribution Share (2007-2008)
    • 16.3 Self Testing, United Kingdom, Company Share (2006-2007)
  • 17 Overview of Key Companies in United Kingdom In Vitro Diagnostics Market
    • 17.1 F. Hoffmann-La Roche Ltd. Company Profile
      • 17.1.1 Company Overview
      • 17.1.2 Value Chain Analysis
        • 17.1.2.1 Manufacturing
        • 17.1.2.2 Product Development
    • 17.2 Abbott Laboratories Company Profile
      • 17.2.1 Company Overview
      • 17.2.2 Value Chain Analysis
        • 17.2.2.1 Manufacturing
        • 17.2.2.2 Product Development
        • 17.2.2.3 Sales and Marketing
    • 17.3 Dade Behring Holdings, Inc. Company Profile
      • 17.3.1 Company Overview
    • 17.4 Ortho-Clinical Diagnostics Inc. Company Profile
      • 17.4.1 Company Overview
      • 17.4.2 Ortho-Clinical Diagnostics Inc. Pipeline Products
        • 17.4.2.1 Ortho-Clinical Diagnostics Inc. Pipeline Products By Equipment Type
        • 17.4.2.2 Ortho-Clinical Diagnostics Inc. Pipeline Products By Development Stage
        • 17.4.2.3 Ortho-Clinical Diagnostics Inc. Pipeline Products By Therapy Area
        • 17.4.2.4 Ortho-Clinical Diagnostics Inc. Pipeline Products By News Summary
    • 17.5 Beckman Coulter, Inc. Company Profile
      • 17.5.1 Company Overview
      • 17.5.2 Value Chain Analysis
        • 17.5.2.1 Manufacturing
        • 17.5.2.2 Product Development
        • 17.5.2.3 Sales and Marketing
      • 17.5.3 Beckman Coulter, Inc. Pipeline Products
        • 17.5.3.1 Beckman Coulter, Inc. Pipeline Products By Equipment Type
        • 17.5.3.2 Beckman Coulter, Inc. Pipeline Products By Development Stage
        • 17.5.3.3 Beckman Coulter, Inc. Pipeline Products By Therapy Area
        • 17.5.3.4 Beckman Coulter, Inc. Pipeline Products By News Summary
    • 17.6 bioMerieux S.A. Company Profile
      • 17.6.1 Company Overview
      • 17.6.2 Value Chain Analysis
        • 17.6.2.1 Manufacturing
        • 17.6.2.2 Product Development
        • 17.6.2.3 Sales and Marketing
    • 17.7 A.Q.S.Manufacturing Ltd Company Profile
      • 17.7.1 Company Overview
    • 17.8 Autogen Bioclear UK Ltd Company Profile
      • 17.8.1 Company Overview
    • 17.9 Axis-Shield plc Company Profile
      • 17.9.1 Company Overview
    • 17.10 Bioline Ltd. Company Profile
      • 17.10.1 Company Overview
    • 17.11 Cambridge Life Sciences Ltd Company Profile
      • 17.11.1 Company Overview
    • 17.12 Cambridge Theranostics Ltd. Company Profile
      • 17.12.1 Company Overview
    • 17.13 Drew Scientific Co. Limited Company Profile
      • 17.13.1 Company Overview
    • 17.14 Enigma Diagnostics Limited Company Profile
      • 17.14.1 Company Overview
    • 17.15 Enzyme Research Laboratories Ltd Company Profile
      • 17.15.1 Company Overview
    • 17.16 Genesis Diagnostics Ltd Company Profile
      • 17.16.1 Company Overview
    • 17.17 Guildhay Limited Company Profile
      • 17.17.1 Company Overview
    • 17.18 Hunter Scientific Limited Company Profile
      • 17.18.1 Company Overview
    • 17.19 Med-Direct International Ltd Company Profile
      • 17.19.1 Company Overview
    • 17.20 The Binding Site Limited Company Profile
      • 17.20.1 Company Overview
  • 18 Financial Deals Landscape
    • 18.1 Acquisition
      • 18.1.1 Oxford Gene Technology Acquires Sense Proteomic
      • 18.1.2 ACM Global Central Laboratory Acquires Pivotal Laboratories from NVM Private Equity
      • 18.1.3 LAB21 Acquires Biotec Laboratories
      • 18.1.4 Gen-Probe Receives Shareholders Approval To Acquire Tepnel Life Sciences
      • 18.1.5 Avacta Group Acquires Theragenetics from IP Group
      • 18.1.6 Acrongenomics Acquires Minority Interest In Molecular Vision
      • 18.1.7 Thermo Fisher Scientific Acquires Raymond A. Lamb
    • 18.2 Partnerships
      • 18.2.1 Seegene Enters Into An Agreement With Randox Laboratories
      • 18.2.2 Mediwatch Enters Into An Agreement With Inverness Medical Innovations
      • 18.2.3 Medizinische Hochschule Hannover Signs An Agreement With Roche Diagnostics
      • 18.2.4 Evogen Enters Into An Agreement With LGC
      • 18.2.5 Illumina Enters Into An Agreement With Oxford Nanopore Technologies
      • 18.2.6 Enigma Diagnostics Enters Into An Agreement With Roche Molecular Systems
      • 18.2.7 Fujirebio Diagnostics Enters Into an Agreement with Roche Diagnostics
  • 19 Recent Developments
    • 19.1 Government and Public Interest
      • 19.1.1 Mar 05, 2009: EMEA Outlines Quality Requirements for Monoclonal Antibodies
      • 19.1.2 Dec 07, 2008: British Researchers Develop New Saliva Test to Spot Cold
      • 19.1.3 Oct 28, 2008: UK Researchers to Develop Blood Test for Pre-Eclampsia
      • 19.1.4 Oct 21, 2008: Blood Test More Accurate Than Skin Test at Detecting TB
      • 19.1.5 Oct 14, 2008: British Scientists to Develop Breath Test That Can Spot Serious Diseases
    • 19.2 Product News
      • 19.2.1 Mar 03, 2009: HemCon Medical Technologies Partners With ProMetic BioSciences to Develop Antibody Capture Device
      • 19.2.2 Feb 03, 2009: Evogen Announces the Launch of High Sensitivity Molecular Diagnostics and Detection Instrument
      • 19.2.3 Jan 08, 2009: Cambridge Temperature Concepts Receives Medical Approval For DuoFertility In Europe
      • 19.2.4 Jan 08, 2009: NuGEN's Ovation Systems Help Almac To Broaden Gene Expression
      • 19.2.5 Dec 16, 2008: Axis-Shield to Develop and Manufacture Active-B12 Assay for Abbott's Architect Analyser
      • 19.2.6 Dec 16, 2008: Lab21 Expands Its Clinical Diagnostic Portfolio With FXG: RESP (Asp +) From Myconostica
      • 19.2.7 Dec 02, 2008: Point Of Care Blood Testing At UK's Largest Polyclinic'
      • 19.2.8 Nov 12, 2008: Illumina Launches Infinium HD Human660W-Quad BeadChip for Advancing Copy Number Variation Analysis Studies
      • 19.2.9 Oct 14, 2008: Ikonisys Reports Positive Results From Clinical Study Designed To Evaluate The Efficacy Of Circulating Tumor Cell Detection With Ikonisys' Automated Microscope
      • 19.2.10 Oct 09, 2008: Illumina Launches mRNA-Seq On The Genome Analyzer
  • 20 Appendix
    • 20.1 Global Markets Direct Research Methodology
    • 20.2 Coverage
    • 20.3 Secondary Research
    • 20.4 Primary Research
    • 20.5 Models
    • 20.6 Forecasts
    • 20.7 Expert Panel Validation
    • 20.8 Currency Conversion
    • 20.9 Contact Us
    • 20.10 Disclaimer
  • 1 List of Tables
    • Table 1: Number of Doctor by Specialty in UK, 2003 - 2007
    • Table 2: United Kingdom Healthcare Trade Statistics, 2001-2006
    • Table 3: Medical Device Approval Fee in UK, 2006
    • Table 4: In Vitro Diagnostics Cross Country Comparison, Revenue ($ mn), 2000-2015
    • Table 5: In Vitro Diagnostics, United Kingdom, Overall Revenue ($ mn), 2000-2015
    • Table 6: In Vitro Diagnostics, United Kingdom, Cross-Category Analysis, 2000-2015
    • Table 7: In Vitro Diagnostics, United Kingdom, Overall Revenue ($ mn), Historic, 2000-2008
    • Table 8: In Vitro Diagnostics, United Kingdom, Overall Revenue ($ mn), Forecast, 2008-2015
    • Table 9: In Vitro Diagnostics, United Kingdom, Company Share by Revenue ($ mn), 2006-2007
    • Table 10: Blood Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 11: Blood Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 12: Haematology Test Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 13: Haematology Test Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 14: Hemostasis Test Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 15: Hemostasis Test Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 16: Blood Test Reagents, United Kingdom, Distribution Share by Revenue ($mn), 2007-2008
    • Table 17: Blood Test Reagents, United Kingdom, Company Share by Revenue ($ mn), 2006-2007
    • Table 18: Clinical Chemistry Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 19: Clinical Chemistry Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 20: Clinical Chemistry Test Reagents, United Kingdom, Distribution Share by Revenue ($mn), 2007-2008
    • Table 21: Clinical Chemistry Test Reagents, United Kingdom, Company Share by Revenue ($ mn), 2006-2007
    • Table 22: Genetic Test Reagents, United Kingdom, Revenue ($ mn), Historic, 2000-2008
    • Table 23: Genetic Test Reagents, United Kingdom, Revenue ($ mn), Forecast, 2008-2015
    • Table 24: Genetic Test Reagents, United Kingdom, Distribution Share by Revenue ($mn), 2007-2008
    • Table 25: Genetic Test Reagents, United Kingdom, Company Share by Revenue ($ mn), 2006-2007
    • Table 26: Immunochemistry Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 27: Immunochemistry Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 28: Disease Specific Markers, United Kingdom, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 29: Disease Specific Markers, United Kingdom, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 30: Disease Specific Test Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 31: Disease Specific Test Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 32: Drug Related Testing Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 33: Drug Related Testing Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 34: Hormone Related Testing Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 35: Hormone Related Testing Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 36: Immunochemistry Test Reagents, United Kingdom, Distribution Share by Revenue ($mn), 2007-2008
    • Table 37: Immunochemistry Test Reagents, United Kingdom, Company Share by Revenue ($ mn), 2006-2007
    • Table 38: Infectious Immunology Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 39: Infectious Immunology Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 40: Virology, United Kingdom, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 41: Virology, United Kingdom, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 42: Infectious Immunology Test Reagents, United Kingdom, Distribution Share by Revenue ($mn), 2007-2008
    • Table 43: Infectious Immunology Test Reagents, United Kingdom, Company Share by Revenue ($ mn), 2006-2007
    • Table 44: Instruments, United Kingdom, Revenue ($ mn), Historic, 2000-2008
    • Table 45: Instruments, United Kingdom, Revenue ($ mn), Forecast, 2008-2015
    • Table 46: Instruments, United Kingdom, Distribution Share by Revenue ($mn), 2007-2008
    • Table 47: Microbiology Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 48: Microbiology Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 49: Bacteriology Test Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 50: Bacteriology Test Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 51: Microbiology Test Reagents, United Kingdom, Distribution Share by Revenue ($mn), 2007-2008
    • Table 52: Microbiology Test Reagents, United Kingdom, Company Share by Revenue ($ mn), 2006-2007
    • Table 53: Self Testing, United Kingdom, Revenue ($ mn), Historic, 2000-2008
    • Table 54: Self Testing, United Kingdom, Revenue ($ mn), Forecast, 2008-2015
    • Table 55: Self Testing, United Kingdom, Distribution Share by Revenue ($mn), 2007-2008
    • Table 56: Self Testing, United Kingdom, Company Share by Revenue ($ mn), 2006-2007
    • Table 57: Ortho-Clinical Diagnostics Inc. Pipeline Products by Equipment Type
    • Table 58: Ortho-Clinical Diagnostics Inc. Pipeline Products By Development Stage
    • Table 59: Ortho-Clinical Diagnostics Inc. Pipeline Products By Therapy Area
    • Table 60: Ortho-Clinical Diagnostics Inc. Pipeline Products By News Summary
    • Table 61: Beckman Coulter, Inc. Pipeline Products by Equipment Type
    • Table 62: Beckman Coulter, Inc. Pipeline Products By Development Stage
    • Table 63: Beckman Coulter, Inc. Pipeline Products By Therapy Area
    • Table 64: Beckman Coulter, Inc. Pipeline Products By News Summary
    • Table 65: Oxford Gene Technology Acquires Sense Proteomic
    • Table 66: ACM Global Central Laboratory Acquires Pivotal Laboratories From NVM Private Equity
    • Table 67: LAB21 Acquires Biotec Laboratories
    • Table 68: Gen-Probe Receives Shareholders Approval To Acquire Tepnel Life Sciences
    • Table 69: Avacta Group Acquires Theragenetics From IP Group
    • Table 70: Acrongenomics Acquires Minority Interest In Molecular Vision
    • Table 71: Thermo Fisher Scientific Acquires Raymond A. Lamb
    • Table 72: Seegene Enters Into An Agreement With Randox Laboratories
    • Table 73: Mediwatch Enters Into An Agreement With Inverness Medical Innovations
    • Table 74: Medizinische Hochschule Hannover Signs An Agreement With Roche Diagnostics
    • Table 75: Evogen Enters Into An Agreement With LGC
    • Table 76: Illumina Enters Into An Agreement With Oxford Nanopore Technologies
    • Table 77: Enigma Diagnostics Enters Into An Agreement With Roche Molecular Systems
    • Table 78: Fujirebio Diagnostics Enters Into An Agreement With Roche Diagnostics
    • Table 79: USD to Local Currency, Average Exchange Rate 2008
  • 1.2 List of Figures
    • Figure 1: Total Healthcare Expenditure in UK, 2000 - 2006
    • Figure 2: Flowchart for Classification of Non-invasive Devices in UK, 2007
    • Figure 3: Flowchart for Classification of Invasive Devices in UK, 2007
    • Figure 4: Flowchart for Classification of Invasive Devices in UK, 2007
    • Figure 5: Flowchart for Classification of Invasive Devices in UK, 2007
    • Figure 6: Flowchart for Classification of Invasive Devices in UK, 2007
    • Figure 7: Flowchart for Classification of Active Devices in UK, 2007
    • Figure 8: Flowchart for Classification of Active Devices in UK, 2007
    • Figure 9: Flowchart for Classification of Devices except Non-invasive, Invasive and Active Devices in UK, 2007
    • Figure 10: Conformity Assessment of Class-I Medical Devices in UK, 2007
    • Figure 11: Conformity Assessment of Class-IIa Medical Devices in UK, 2007
    • Figure 12: Conformity Assessment of Class-IIb Medical Devices in UK, 2007
    • Figure 13: Conformity Assessment of Class-III Medical Devices in UK, 2007
    • Figure 14: In Vitro Diagnostics Cross Country Comparison, Revenue ($ mn), 2000-2015
    • Figure 15: In Vitro Diagnostics, United Kingdom, Overall Revenue ($ mn), 2000-2015
    • Figure 16: In Vitro Diagnostics, United Kingdom, Cross-Category Analysis, 2000-2015
    • Figure 17: In Vitro Diagnostics, United Kingdom, Overall Revenue ($ mn), Historic, 2000-2008
    • Figure 18: In Vitro Diagnostics, United Kingdom, Overall Revenue ($ mn), Forecast, 2008-2015
    • Figure 19: In Vitro Diagnostics, United Kingdom, Company Share (%), 2007
    • Figure 20: Blood Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 21: Blood Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 22: Haematology Test Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 23: Haematology Test Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 24: Hemostasis Test Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 25: Hemostasis Test Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 26: Blood Test Reagents, United Kingdom, Company Share (%), 2007
    • Figure 27: Clinical Chemistry Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 28: Clinical Chemistry Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 29: Clinical Chemistry Test Reagents, United Kingdom, Company Share (%), 2007
    • Figure 30: Genetic Test Reagents, United Kingdom, Revenue ($ mn), Historic, 2000-2008
    • Figure 31: Genetic Test Reagents, United Kingdom, Revenue ($ mn), Forecast, 2008-2015
    • Figure 32: Genetic Test Reagents, United Kingdom, Company Share (%), 2007
    • Figure 33: Immunochemistry Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 34: Immunochemistry Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 35: Disease Specific Markers, United Kingdom, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 36: Disease Specific Markers, United Kingdom, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 37: Disease Specific Test Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 38: Disease Specific Test Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 39: Drug Related Testing Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 40: Drug Related Testing Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 41: Hormone Related Testing Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 42: Hormone Related Testing Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 43: Immunochemistry Test Reagents, United Kingdom, Company Share (%), 2007
    • Figure 44: Infectious Immunology Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 45: Infectious Immunology Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 46: Virology, United Kingdom, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 47: Virology, United Kingdom, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 48: Infectious Immunology Test Reagents, United Kingdom, Company Share (%), 2007
    • Figure 49: Instruments, United Kingdom, Revenue ($ mn), Historic, 2000-2008
    • Figure 50: Instruments, United Kingdom, Revenue ($ mn), Forecast, 2008-2015
    • Figure 51: Microbiology Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 52: Microbiology Test Reagents, United Kingdom, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 53: Bacteriology Test Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 54: Bacteriology Test Reagents, United Kingdom, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 55: Microbiology Test Reagents, United Kingdom, Company Share (%), 2007
    • Figure 56: Self Testing, United Kingdom, Revenue ($ mn), Historic, 2000-2008
    • Figure 57: Self Testing, United Kingdom, Revenue ($ mn), Forecast, 2008-2015
    • Figure 58: Self Testing, United Kingdom, Company Share (%), 2007
    • Figure 59: F. Hoffmann-La Roche Ltd Value Chain Analysis
    • Figure 60: Abbott Laboratories Value Chain Analysis
    • Figure 61: Beckman Coulter, Inc. Value Chain Analysis
    • Figure 62: Biomerieux Sa Value Chain Analysis
    • Figure 63: Global Markets Direct Methodology